Lv0
0 积分 2025-11-02 加入
Recent findings on the PD-1/PD-L1 Axis in breast cancer: Molecular mechanisms, immunotherapeutic potentials, and clinical implications
5个月前
已完结
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer
5个月前
已完结
Advancements in clinical research and emerging therapies for triple-negative breast cancer treatment
5个月前
已完结
IL1R2 Blockade Alleviates Immunosuppression and Potentiates Anti-PD-1 Efficacy in Triple-Negative Breast Cancer
5个月前
已完结
Tumor-derived arachidonic acid reprograms neutrophils to promote immune suppression and therapy resistance in triple-negative breast cancer
5个月前
已完结
Towards targeting the breast cancer immune microenvironment
6个月前
已完结
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer
6个月前
已完结
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
6个月前
已完结
Efficacy and Safety of Pembrolizumab Monotherapy or Combined Therapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
6个月前
已完结
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
6个月前
已完结
皖公网安备34019202002308
